Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ:FENC) granted inducement incentive stock options to one new non-executive employee under its 2026 Equity Inducement Plan. The award covers 15,000 common shares at an exercise price of $9.06 per share, with a ten-year term and time-based vesting.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – FENC
On the day this news was published, FENC gained 5.19%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.4% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $18M to the company's valuation, bringing the market cap to $366.48M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
FENC was up before this news, while momentum peers were mixed, with one notable decliner (NMRA) and two gainers (AVIR, DBVT), suggesting stock-specific rather than broad sector-driven action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 15 | Inducement grant | Neutral | +2.1% | Options grant of 10,000 shares to a new employee under inducement plan. |
| Jun 10 | Annual meeting results | Neutral | +1.7% | Shareholders approved directors, auditor, compensation, and equity plan amendments. |
| May 21 | Clinical data update | Positive | -0.4% | New PEDMARK research and trial data presented at the 2026 ASCO Annual Meeting. |
| May 18 | Inducement grants | Neutral | +1.7% | Stock options for 50,000 shares granted to new employees under inducement plan. |
| May 14 | Earnings and update | Positive | +36.5% | Strong Q1 revenue growth, turn to net income, and expanded PEDMARK studies. |
Recent FENC news has generally seen positive or modestly positive price reactions, with only one slight divergence on ASCO-related data.
Regulatory & Risk Context
Reported short interest is low, indicating limited short-positioning pressure and a relatively lower risk of short-squeeze-driven volatility based on current data.
Market Pulse Summary
The stock moved +5.2% in the session following this news. A strong positive reaction aligns with FENC’s history of constructive responses to governance and compensation updates, though repeated equity awards still add incremental dilution risk alongside existing insider net selling activity.
Key Terms
incentive stock option financial
nasdaq listing rule 5635(c)(4) regulatory
equity inducement plan financial
exercise price financial
vesting financial
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company’s Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company’s common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company’s 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).
All ISOs have an exercise price of
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI® is now commercially available in the U.K. and Germany.
PEDMARK® has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI® has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
Forward Looking Statements
Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about the Company’s business strategy, timeline and other goals, plans and prospects, including the Company’s commercialization plans respecting PEDMARK®/PEDMARQSI®, the market opportunity for and market impact of PEDMARK®/ PEDMARQSI®, its potential impact on patients and anticipated benefits associated with its use, future commercial and regulatory milestone and royalty payments from Norgine, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company’s ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2025. Fennec disclaims any obligation to update these forward-looking statements except as required by law.
For a more detailed discussion of related risk factors, please refer to the Company’s public filings available at www.sec.gov and www.sedar.com.
PEDMARK®, PEDMARQSI® and Fennec® are registered trademarks of Fennec Pharmaceuticals Inc.
©2025 Fennec Pharmaceuticals Inc. All rights reserved
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
